AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

Multi-center, multi-national study to evaluate mechanical thrombectomy treatment in acute, intermediate-risk PE patients in European Market

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of the Prospective, Multicenter, Multi-national, Single Arm Trial Evaluating the Efficacy, Safety and long term functional outcomes of percutaneous mechanical aspiration thrombectomy for Treatment of Acute Pulmonary Embolism (PE) using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F18⁸⁵ System (RECOVER-AV).

The RECOVER-AV trial is designed to evaluate the safety and efficacy of AlphaVac for the treatment of acute, intermediate-risk PE to support its adoption in the European market.

This study follows the Acute Pulmonary Extraction Trial with AlphaVac (APEX-AV) study, a single-arm Investigational Device Exemption study that enrolled 122 patients with confirmed acute, intermediate-risk PE across 25 hospital-based sites in the United States to assess the AlphaVac F18⁸⁵ System for the treatment of PE. APEX-AV, which completed enrollment in December 2023, demonstrated that the AlphaVac F18⁸⁵ System is safe in patients with acute intermediate-risk PE and provides significant improvement in right ventricular function and reduction in clot burden.

The RECOVER-AV study is a multi-center, multi-national trial enrolling patients with confirmed acute, intermediate-risk PE across up to 20 hospital sites in Europe. The primary efficacy endpoint is the reduction of the right ventricular/left ventricular (RV/LV) ratio from baseline to 48 hours post-procedure. The primary safety endpoint focuses on the incidence of Major Adverse Events (MAEs), such as device-related death or major bleeding within seven days. Patients will be followed for 12-months, with functional outcomes assessed at 30-days, six-months, and 12-months.

An estimated 435,000 PE events occur each year in the six largest European Union (EU) countries.¹ Compared to the United States, the prevalence of PE is higher for those patients admitted to the emergency department in Europe, and European patients also had higher acuity and worse outcomes.²

“We are excited to launch this important trial as we assess the performance of the AlphaVac F18⁸⁵ System in patients with intermediate-risk pulmonary embolisms,” said Laura Piccinini, AngioDynamics Senior Vice President and General Manager of Endovascular Therapies and International. “With our clinical partners, we are demonstrating our continued commitment to generating robust clinical evidence across the world, with this being the first international study we have sponsored highlighting our commitment as a global leader to treat more patients and advance care.”

In May, the Company announced that its AlphaVac F18⁸⁵ System received CE Mark approval in Europe for the non-surgical removal of thrombi or emboli from pulmonary arteries, including for treating PE. This approval allows the Company to expand its reach in the European market, where PE prevalence is notably higher than in the U.S.² The AlphaVac F18⁸⁵ System is designed to enhance treatment options for healthcare professionals and improve outcomes for patients suffering from PE.

The Study is led by co-Principal Investigators Erik Klok, MD, Professor of Medicine and Vascular Medicine Specialist at Leiden University Medical Center, and Andrew Sharp, MD, Professor of Interventional Cardiology at Mater Misericordiae Hospital and University College Dublin.

They are supported by an internationally renowned Scientific Advisory Board featuring leading experts in pulmonary embolism (PE) and related fields, including Prof. Menno Huisman (Leiden UMC, Netherlands), John Moriarty, MD (UCLA, USA), Prof. Makis Avgerinos (University of Athens, Greece), Prof. Irene Lang (Medical University of Vienna, Austria), Julie Helms, MD (CHRU Strasbourg, France), and Sebastian Stefaniak, MD, and Mateusz Puslecki, MD (PUMS, Poland).

About the AlphaVac F18⁸⁵ System

The AlphaVac F18⁸⁵ System is an emergent first-line device that is currently CE marked for the non-surgical removal of thromboemboli from the pulmonary arteries and for the treatment of PE. The System includes an ergonomic handle, an 18F cannula with an 85-degree angle, an obturator, and a waste bag assembly. For risk information, visit https://bit.ly/Angio-risk-info.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign healthcare reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

AngioDynamics, the AngioDynamics logo and AlphaVac are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are property of their respective owners.

___________________________________

1 Willich SN, Chuang LH, van Hout B, Gumbs P, Jimenez D, Kroep S, Bauersachs R, Monreal M, Agnelli G, Cohen A. Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res. 2018 Oct;170:181-191.

2 Germini F., Zarabi S., Eventov M., Turcotte M., Li M., de Wit K. Pulmonary embolism prevalence among emergency department cohorts: A systematic review and meta‐analysis by country of study. Journal of Thrombosis and Haemostasis. 2022 Dec; 19(1):173-185

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240919696998/en/

Investor:

Stephen Trowbridge

Executive Vice President & CFO

518-795-1408

strowbridge@angiodynamics.com

Media:

Saleem Cheeks

Vice President, Communications

518-795-1174

scheeks@angiodynamics.com

Source: AngioDynamics, Inc.

FAQ

What is the purpose of AngioDynamics' RECOVER-AV clinical trial for ANGO stock?

The RECOVER-AV trial aims to evaluate the safety and efficacy of the AlphaVac F18⁸⁵ System in treating acute, intermediate-risk pulmonary embolism (PE) to support its adoption in the European market.

How many patients and sites were involved in the APEX-AV study for ANGO's AlphaVac System?

The APEX-AV study enrolled 122 patients with confirmed acute, intermediate-risk PE across 25 hospital-based sites in the United States.

What are the primary endpoints of the RECOVER-AV trial for AngioDynamics (ANGO)?

The primary efficacy endpoint is the reduction of the right ventricular/left ventricular ratio from baseline to 48 hours post-procedure. The primary safety endpoint is the incidence of Major Adverse Events within seven days.

When did AngioDynamics (ANGO) receive CE Mark approval for the AlphaVac F18⁸⁵ System in Europe?

AngioDynamics announced in May that its AlphaVac F18⁸⁵ System received CE Mark approval in Europe for the non-surgical removal of thrombi or emboli from pulmonary arteries, including for treating PE.